Foley Partner Steven Vazquez was quoted in an article that appeared in the October 2011 issue of Boardroom INSIDER titled “Q&A: How Can We Make CEO/Board Evaluation Better?” Vazquez provides updates from a seminar he led on CEO and board evaluation issues as part of Foley’s National Director’s Institute Checkpoint Web Conference series. Discussing Say-On-Pay votes, Vazquez states that low marks on a CEO evaluation combined with a pay increase could be detrimental to a company if a disgruntled investor sues and uses the evaluations to shed light on embarrassing board work. He adds that evaluations are potentially an effective tool for directors to share ideas on board management, noting that the evaluation process is often an underused tool for weighing the company’s strategy, talent and compensation structures against outside benchmarks.
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.